社区

ZKH Group's American depositary receipts rose after the company's board authorized the repurchase of up to $50 million shares over the next year.The stock was up 12% at $4.61 in premarket trading on Friday. Shares started trading in December and have fallen by three quarters since the start of the year.The maintenance, repair and operations procurement service platform said after the bell on Thursday that the authorization runs through June 13 of next year.

On Friday, Summit Therapeutics Inc shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday.Thursday, Summit Therapeutics Inc announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival .HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression .The HARMONi-2 is a single-region, multi-center, double-blinded Phase 3 study conducted in China sponsored by Akeso Inc. with data generated and analyzed by Akeso.At a prespecified interim analysis conducted by an independent Data Monitoring Committee, ivonescimab demonstrated a statistically significant and clinically meaningful improvement in PFS by the blinded independent central radiology review committee compared to Merck & Co Inc’s Keytruda .The progression-free survival benefit was demonstrated across clinical subgroup

$Faraday Future(FFIE)$ 真无语啊，我割完肉你就涨……

$Faraday Future(FFIE)$ 真无语啊，我割完肉你就涨……

$Faraday Future(FFIE)$ 兄弟们冲啊！只要不卖就能上天！